Señales en vivo de AREC.L | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 11:23):

Stats
Volumen de hoy	18 966.00
Volumen promedio	14 109.00
Capitalización de mercado	42.11M
EPS	£0 ( 2024-04-21 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-4.44
ATR14	£0 (0.00%)

Arecor Therapeutics plc Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas
DPEU.L	-0.848
LRE.L	-0.811
RMMC.L	-0.807

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arecor Therapeutics plc Finanzas

Annual	2022
Ingresos:	£2.40M
Beneficio Bruto:	£2.40M (100.00 %)
EPS:	£-0.320

FY	2022
Ingresos:	£2.40M
Beneficio Bruto:	£2.40M (100.00 %)
EPS:	£-0.320

FY	2021
Ingresos:	£1.16M
Beneficio Bruto:	£1.16M (100.00 %)
EPS:	£-0.270

FY	2020
Ingresos:	£1.70M
Beneficio Bruto:	£1.70M (100.00 %)
EPS:	£-0.0994

Financial Reports:

No articles found.

Arecor Therapeutics plc

Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.